$14.49
+0.03 (+0.21%)
Performance
1D
—
1W
—
1M
—
3M
+1.33%
6M
+61.00%
1Y
+142.31%
YTD
+1.54%
Open$14.49
Previous Close$14.46
Day High$14.50
Day Low$14.49
52W High$14.50
52W Low$5.51
Volume—
Avg Volume3.08M
Market Cap4.55B
P/E Ratio—
EPS$-0.09
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$13.59
Above
SMA 200
$8.96
Above
RSI (14)
72.2
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
14 analysts
Price Target
+619.5% upside
Current
$14.49
$14.49
Target
$104.26
$104.26
$68.91
$104.26 avg
$125.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 645.81M | 519.01M | 353.38M |
| Net Income | -27,600,664 | -19,963,511 | 71.26M |
| Profit Margin | -4.3% | -4.1% | 20.2% |
| EBITDA | 51.40M | 39.24M | 123.65M |
| Free Cash Flow | — | — | 60.51M |
| Rev Growth | +24.4% | +24.4% | +12.1% |
| Debt/Equity | 1.43 | 1.43 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |